Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > OMER > Summary

Omeros Corporation
(OMER)

7.50USD   0.00 (0.00%)   
On Nov 21
 Omeros Corporation (NGM:OMER) Delayed quote data 
[Chart]
1d  5d  3m 
Last Trade: 7.50USD
Trade Time:Nov 21
Change:0.00 (0.00%)
Prev Close:7.50
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:12.25
Day's Range:N/A - N/A
52wk Range:5.27 - 9.49
Volume:0
Avg Vol (3m):188,147
Market Cap:22.15M
P/E (ttm):N/A
EPS (ttm):-8.68
Div & Yield:N/A (N/A%)
Add OMER to Portfolio   Download Data

HEADLINES

 
•New Star Analyst Rankings for Omeros Corporation - StarMine  - Sun 7:49PM
•Coverage initiated on Omeros by Wedbush Morgan - Briefing.com  - Fri, Nov 20
•OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition - EDGAR Online  - Fri, Nov 20
•Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights - PR Newswire  - Fri, Nov 20
•Q3 2009 OMEROS CORP Earnings Release - After Market Close - CCBN  - Thu, Nov 19
•Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19 - PR Newswire  - Fri, Nov 13
•OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement - EDGAR Online  - Thu, Nov 12
•CEO Interview: Winston Pharmaceuticals, Inc. - Dr. Joel E. Bernstein - Wall Street Transcript  - Tue, Nov 3
•Hyatt Hotels to Test the IPO Waters - The Wall Street Journal Online  - Mon, Nov 2
•Road to Market Becomes More Difficult in the U.S. - The Wall Street Journal Online  - Mon, Nov 2
» More Headlines for OMER...

ANALYST

 
EPS Est (next year) (Dec-09) :-1.44
EPS Est (in 2 years) (Dec-10) :-1.47
Avg Rec (current)*:1.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system.

» Full Company Profile